Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD)

Journal of Clinical Epidemiology
M T NiuSusan S Ellenberg

Abstract

Preliminary review of data from the Vaccine Adverse Event Reporting System (VAERS), 1991-1994, revealed that more serious adverse events were reported in children who received a specific brand of recombinant hepatitis B (HepB) vaccine. To compare the post-marketing safety experience of the two recombinant HepB vaccines licensed for use in infants and children in the United States. Review of a case series derived from passive surveillance data in the national VAERS. A retrospective cohort study using data from one health maintenance organization participating in Vaccine Safety Datalink (VSD), a computerized record linkage system. POPULATIONS STUDIED: U.S. children, ages birth-10 years for whom adverse events after HepB vaccine were reported to VAERS, 1991-1994. Children, ages birth-6 years, who received HepB vaccine at Kaiser Permanente Medical Care Program, Northern California, 1991-1994. VAERS reporting rates for each vaccine by manufacturer were calculated from the numbers of reported events occurring within 30 days of HepB vaccination and the number of doses distributed by the manufacturers. VSD event rates for each vaccine were calculated from the numbers of hospitalization or emergency room visits within 30 days of HepB va...Continue Reading

References

Feb 1, 1991·Revue de l'infirmière·A Montloin
Jun 9, 1989·JAMA : the Journal of the American Medical Association·Y PoovorawanA Safary
Sep 4, 1989·The American Journal of Medicine·F E André
Jun 1, 1989·American Journal of Infection Control·D J West
Jul 1, 1986·The Journal of Infection·B A ZajacE M Scolnick
Sep 1, 1983·The Journal of Infectious Diseases·G C LeeT Y Lee
Jul 1, 1983·The Journal of Infection·A A McLeanE B Buynak
Dec 1, 1995·American Journal of Public Health·S Rosenthal, R Chen
May 1, 1994·Vaccine·R T ChenS G Wassilak

❮ Previous
Next ❯

Citations

Aug 7, 2003·The Journal of Emergency Medicine·Mardi SteerePhyllis H Stenklyft
May 24, 2003·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Mark R GeierArthur C Zahalsky
Apr 9, 2004·The Pediatric Infectious Disease Journal·Frederick VarricchioRobert T Chen
Aug 31, 2006·The Pediatric Infectious Disease Journal·Lindsay A ThompsonFrank Chimkin
Aug 18, 2000·Paediatric Drugs·R T ChenF DeStefano
Jun 17, 2008·American Journal of Public Health·Jesse A BerlinSusan S Ellenberg
Jul 26, 2015·Human Vaccines & Immunotherapeutics·G MenaJ M Bayas
Dec 29, 1998·Journal of Toxicology. Clinical Toxicology·F Varricchio
Dec 19, 2001·Emerging Infectious Diseases·A E BarnatoD K Owens
May 13, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·John IskanderUNKNOWN VAERS Team
May 2, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·T Jefferson, H Heijbel
Apr 12, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Susan S Ellenberg, Miles M Braun
Dec 6, 2011·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Andrew BateManfred Hauben
May 30, 2003·Experimental Biology and Medicine·Mark R Geier, David A Geier
Dec 6, 2011·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Colin John CrooksStephen J W Evans
Jan 22, 2005·Pharmacoepidemiology and Drug Safety·Gustavo H DayanRobert Chen
Jul 20, 2010·Clinica Chimica Acta; International Journal of Clinical Chemistry·José G Dórea

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.